SDH of HPV Vaccine Completion

Duke University

Status: Completed

Conditions: Human Papilloma Virus

Study type: Observational

Funder types: Other

Identifiers

NCT03709602

Pro00100733

Details and patient eligibility

About

The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child. The information learned from this study may help the investigators develop programs to improve HPV vaccine completion rates among adolescents and reduce barriers to receiving the second shot of the vaccine series.

Enrollment: 3,076 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• For adolescents, participants need to be between the ages 11 to 14 years.
• Received 1 dose of the HPV vaccine series between January 2017 and December 2017.
• For parents, there is no age limit required.
• Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian.
• Parents or legal guardians who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.

Exclusion criteria

• Parents with cognitive impairment.
• Adolescents with cognitive impairment.
• Adolescents emancipated from their parents or legal guardian
• Pregnant adolescent girls.

Trial design

3,076 participants in 3 patient groups

Adolescents ages 11 to 14 years

Description:

Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017

Parent of adolescents

Description:

Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.

Cohort of Adolescents From Electronic Health Record (EHR)

Description:

A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.